Serologic testing in celiac disease: Practical guide for clinicians.

Primary care clinicians often face uncertainty when deciding which tests to order for celiac disease. Prior research has established that celiac disease is a common autoimmune condition with varied symptoms. However, no prior work had resolved the best approach for selecting and interpreting serologic tests. Selective IgA deficiency can lead to false-negative results, which complicates diagnosis. Guidelines on CD testing are not always clear to non-specialists. This gap motivated the need for a focused review of current evidence. Understanding the role of IgA tissue transglutaminase antibody is key to accurate screening. The absence of a definitive test without biopsy remains a challenge in clinical practice.

This review aimed to clarify the role of serologic testing in celiac disease for primary care physicians. The study focused on the practical aspects of test selection and interpretation. The motivation was to reduce diagnostic delays and improve patient outcomes. No prior work had synthesized the most recent guidelines into a clinician-friendly format. The authors sought to address common questions about test accuracy and limitations. They emphasized the importance of confirming results with biopsy. The review also aimed to highlight the role of genetic testing in excluding CD. The goal was to provide actionable insights for non-specialists in a busy clinical setting.

The authors conducted a MEDLINE search for guidelines on celiac disease from 2000 to 2015. Only English-language documents from gastroenterological organizations were included. The focus was on serologic testing recommendations and their clinical application. The study did not include randomized trials or case reports. The data were synthesized to identify best practices for primary care. The authors evaluated the role of IgA tissue transglutaminase antibody as a first-line test. They also assessed the utility of HLA-DQ2 and HLA-DQ8 testing in diagnostic exclusion. The review approach emphasized clarity and practicality for non-specialist clinicians.

The IgA tissue transglutaminase antibody test is recommended as the first-line screening tool. Total serum IgA should be measured to avoid false-negative results in IgA-deficient patients. Positive serologic results require confirmation with small intestinal biopsies. HLA-DQ2 and HLA-DQ8 testing can help rule out CD in some cases. Gluten-free diets should not be initiated before a confirmed diagnosis. Early testing leads to earlier diagnosis and fewer complications. The study found that serologic testing is highly useful in screening for CD. The results emphasize the need for collaboration between primary care and gastroenterology.

The authors concluded that IgA tissue transglutaminase antibody is the preferred initial test for CD. They emphasized the importance of measuring total IgA to avoid diagnostic errors. Serologic testing alone is insufficient for a definitive diagnosis. Endoscopic biopsy remains necessary for confirmation. HLA testing can provide additional diagnostic clarity in some patients. Gluten-free diets should not be started before a confirmed diagnosis. The study highlights the value of early testing in preventing complications. The authors propose that a stepwise approach improves diagnostic accuracy and patient outcomes.